Orexo AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000736415
SEK
14.34
-0.02 (-0.14%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of -10.25% and Operating profit at -247.13% over the last 5 years
  • The company is Net-Debt Free
2

The company has declared negative results for the last 3 consecutive quarters

3

Risky -

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 632 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-130.15%

stock-summary
Price to Book

2.33

Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2026)
Net Profit:
-102 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.33%
0%
-20.33%
6 Months
-49.33%
0%
-49.33%
1 Year
-28.3%
0%
-28.3%
2 Years
-4.4%
0%
-4.4%
3 Years
-19.07%
0%
-19.07%
4 Years
-45.48%
0%
-45.48%
5 Years
-60.6%
0%
-60.6%

Orexo AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-10.25%
EBIT Growth (5y)
-247.13%
EBIT to Interest (avg)
-13.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.24
Sales to Capital Employed (avg)
1.00
Tax Ratio
0.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.77
EV to EBIT
-1.16
EV to EBITDA
-1.62
EV to Capital Employed
-15.32
EV to Sales
1.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-79.63%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -30.00% vs 51.52% in Mar 2026",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 2.57% vs 9.00% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.50",
          "val2": "5.00",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-100.00",
          "val2": "-74.20",
          "chgp": "-34.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "29.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-102.50",
          "val2": "-105.20",
          "chgp": "2.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-30,914.30%",
          "val2": "-16,600.00%",
          "chgp": "-1,431.43%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -12.46% vs -95.35% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 15.63% vs -272.56% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26.00",
          "val2": "29.70",
          "chgp": "-12.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-279.90",
          "val2": "-300.50",
          "chgp": "6.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "50.30",
          "val2": "60.00",
          "chgp": "-16.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-403.30",
          "val2": "-478.00",
          "chgp": "15.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,342.30%",
          "val2": "-15,676.80%",
          "chgp": "233.45%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
3.50
5.00
-30.00%
Operating Profit (PBDIT) excl Other Income
-100.00
-74.20
-34.77%
Interest
0.00
29.20
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-102.50
-105.20
2.57%
Operating Profit Margin (Excl OI)
-30,914.30%
-16,600.00%
-1,431.43%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is -30.00% vs 51.52% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 2.57% vs 9.00% in Mar 2026

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
26.00
29.70
-12.46%
Operating Profit (PBDIT) excl Other Income
-279.90
-300.50
6.86%
Interest
50.30
60.00
-16.17%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-403.30
-478.00
15.63%
Operating Profit Margin (Excl OI)
-13,342.30%
-15,676.80%
233.45%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -12.46% vs -95.35% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 15.63% vs -272.56% in Dec 2024

stock-summaryCompany CV
About Orexo AB stock-summary
stock-summary
Orexo AB
Pharmaceuticals & Biotechnology
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Company Coordinates stock-summary
Company Details
Rapsgatan 7E , UPPSALA None : 754 50
stock-summary
Tel: 46 18 780880046 73 0641636
stock-summary
Registrar Details